摩根大通将Biogen上调至超配并设目标价300美元，股价盘前约涨2%

Biogen ( BIIB ) shares rose 2.1% in Monday’s premarket trading after JPMorgan upgraded the stock to overweight from neutral, citing an increasingly attractive pipeline of catalysts expected in 2027. The brokerage set a PT of $300, which implies a 33% increase from last close. Analyst Christopher Schott also cites an “improved long-term growth outlook for the company,” according to media reports. “Net-net, we see BIIB ( BIIB ) as one of the more attractive names to own heading into 2027 as the company evolves beyond just a Leqembi story,” the analyst said. Earlier this month BIIB said its experimental drug showed durable improvement in skin symptoms among patients with a type of ​autoimmune disease in a mid-stage study. However, Biogen faces mounting pressure on its legacy multiple sclerosis portfolio from pricing ​challenges and competition, prompting it to rely on newer ​products, including Alzheimer's drug Leqembi, to revive growth. SA Quant rates the stock Hold (3.11) , while Wall Street analysts maintain a Buy rating with an average score of 4.11 .